HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its European Patent Office Application EP3834729 has been granted.

Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms. Diastolic dysfunction is caused by all common issues that affect heart function or that produce hypertrophy. All patients with heart disease have diastolic dysfunction, in contrast to systolic dysfunction (reduced pumping of blood by the heart, or reduced ejection fraction), which only affects a subset of patients and typically occurs at a more severe, often symptomatic, stage of heart disease.

Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging. The ability to assess cardiac diastolic function using an ECG makes it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.

"We are pleased to receive this latest patent grant which further reinforces our position at the forefront of AI-ECG. This patent is particularly valuable because it covers the use of AI-ECG to produce any echo measure of diastolic function, which is fundamental to screen for a broad range of heart disease at an early stage," said Andrew Simpson, CEO of HeartSciences.

The United States Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences, with patent expiration dates ranging from March 2031 through August 2040. HeartSciences also has 14 international design registrations and 20 international utility patents granted in jurisdictions such as China, Japan, South Korea, the United Kingdom, France, Germany, Mexico, the United Arab Emirates, Brazil, and Australia.